Overall, these findings suggest that targeting ROS could be an effective strategy for glioblastoma treatment by disrupting the HIF-1α-SERPINE1 signaling pathway that promotes tumor progression in hypoxic environments [68]. This evidence concerns the gene HIF1A and glioblastoma.